

Applicant: Peled et al.


Remarks

Upon entry of the amendment, claims 201-243 will be pending in the application. Claims 1-200 are cancelled and claims 201-243 are added. Support for the new claims appears in original claims 1-200 as filed and, for new claims 238 and 239, at page 34, lines 27-30 (disclosing using hematopoietic mononuclear cells as a direct source for obtaining expanded population of hematopoietic stem cells with stem cell enrichment prior to expansion). No new matter is added.

Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below. The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Reference No. 24024-506.

Dated: January 29, 2004

Respectfully submitted,


FOR Ivor R. Eriq, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No.: 30623

TRA 1849812v2